Community Health Systems, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing; the supplied filing text does not provide a clear standalone fourth-quarter income statement.
Business context
CHS operated 89 hospitals with 14,110 licensed beds across 16 states at year-end. Its hospital and outpatient businesses serve patients covered by government programs, commercial payors, and self-pay arrangements. The company completed 13 hospital divestitures during 2020 and received approximately $845 million in net proceeds, including proceeds received at preliminary closings in 2019.
Financial and operating performance
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net operating revenue | $11.789 billion | $13.210 billion |
| Income (loss) from operations | $1.126 billion | $650 million |
| Net income (loss) | $607 million | $(590) million |
| Net income (loss) attributable to CHS stockholders | $511 million | $(675) million |
| Adjusted EBITDA (non-GAAP) | $1.809 billion | $1.628 billion |
| Net cash from operating activities | $2.178 billion | $385 million |
| Cash and cash equivalents at year-end | $1.676 billion | $216 million |
| Total debt, net of issuance costs and discounts/premiums | $12.216 billion | $13.405 billion |
- Revenue declined 10.8%; same-store revenue fell 3.4%. Consolidated admissions decreased 15.7% and adjusted admissions decreased 19.4%. Same-store admissions and adjusted admissions declined 8.0% and 12.5%, respectively.
- Income from operations was 9.6% of revenue, versus 4.9% in 2019. Adjusted EBITDA margin was 15.3%, versus 12.3%. The filing cautions that Adjusted EBITDA is a non-GAAP measure and may not be comparable across companies.
- Cash from operations rose sharply, reflecting pandemic-related relief and Medicare advance payments as well as working-capital movements. It should not be viewed as recurring operating cash generation without adjustment.
- Cash capital expenditures were $440 million, including $117 million for replacement hospitals. Net cash used in financing activities was $895 million; cash interest paid was approximately $1.039 billion.
- Net working capital was approximately $1.7 billion. The ABL facility had no borrowings and approximately $529 million of available capacity after borrowing-base limits and letters of credit. Current maturities of long-term debt were $123 million.
- Debt remained substantial: the filing reports approximately $12.2 billion of debt and debt equal to 114% of total capitalization. Approximately 100% of outstanding debt had fixed interest rates at year-end.
Material changes and unusual items
- COVID-19 and hospital divestitures drove lower revenue and patient volumes. Same-store revenue was down $396 million year over year; volumes improved from the March–April 2020 lows but had not returned to pre-pandemic levels.
- CHS received approximately $705 million in pandemic relief payments through federal, state, and local programs, net of amounts repaid or expected to be repaid. It recognized approximately $601 million as a reduction in operating costs and expenses; approximately $104 million remained unrecognized at year-end, subject to eligibility and reporting requirements.
- CHS received approximately $1.2 billion of Medicare accelerated payments in April 2020; approximately $1.081 billion remained outstanding at year-end and is repayable through future Medicare payment recoupments.
- FY2020 stockholder-attributable net income included a $317 million pretax gain from early extinguishment of debt and a substantial tax benefit, including approximately $240 million of discrete benefits related to tax valuation allowances. It also included an approximately $50 million professional-liability settlement expense for which insurance coverage is being litigated.
- Debt refinancing and repurchases reduced reported debt and generated the debt-extinguishment gain. After year-end, the company redeemed remaining 2023 secured notes and 2024 senior secured notes and issued additional notes due 2029 and 2031; these transactions changed the maturity and interest profile after the balance-sheet date.
Outlook, risks, and contingencies
Management did not provide formal numerical earnings or revenue guidance in the supplied text. It expected COVID-19 to continue materially affecting financial performance and said patient volumes remained below pre-pandemic levels. Management estimated 2021 capital expenditures of approximately $400–$500 million and stated it expected available cash, operating cash flows, ABL capacity, capital-market access, and divestiture proceeds to support operations and investment over the next 12 months.
- Key risks include pandemic-related volume and cost volatility, staffing and supply constraints, collection deterioration, reimbursement and payor-contract pressure, regulatory changes, and concentration of revenue in Indiana, Florida, and Texas.
- Leverage, debt maturities, restrictive covenants, and the need to maintain refinancing and capital-market access remain important risks. Debt agreements restrict certain subsidiary distributions and other actions.
- CHS is subject to ongoing legal, regulatory, and governmental matters. Management said pending matters were not expected to materially affect consolidated financial position or liquidity, but an adverse result could materially affect results or cash flows in a particular period. The company’s Corporate Integrity Agreement runs through September 2021; material noncompliance could lead to penalties or exclusion from government programs.
- Professional-liability estimates are judgmental: the recorded liability was $602 million at year-end. The $50 million settlement with disputed insurer coverage is a separate notable exposure.
- Approximately $4.2 billion of goodwill remained on the balance sheet. No impairment was indicated in the 2020 annual test, but future declines in volumes, revenue, or valuation assumptions could trigger a material non-cash charge.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Patient accounts receivable and professional-liability reserves were identified as critical audit matters.
Important facts for investors to verify
- How much of the 2020 operating cash flow and earnings improvement is sustainable after separating relief funds, Medicare advances, tax benefits, divestitures, and debt-extinguishment gains.
- The repayment and recoupment schedule for approximately $1.081 billion of Medicare accelerated payments, and whether all recognized relief funds satisfy HHS requirements.
- Updated patient volumes, same-store revenue trends, and uninsured-patient collections relative to pre-pandemic levels.
- Debt maturities, refinancing costs, covenant headroom, and the effect of the post-year-end refinancing transactions on interest expense and liquidity.
- Developments in the professional-liability insurance coverage litigation, other significant legal proceedings, and compliance with the Corporate Integrity Agreement.